Oramed Pharmaceuticals (ORMP) Competitors $2.27 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.25 -0.02 (-0.84%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. FDMT, ENGN, KMDA, YMAB, AMRN, TVRD, AURA, DRUG, REPL, and DMACShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include 4D Molecular Therapeutics (FDMT), enGene (ENGN), Kamada (KMDA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Tvardi Therapeutics (TVRD), Aura Biosciences (AURA), Bright Minds Biosciences (DRUG), Replimune Group (REPL), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors 4D Molecular Therapeutics enGene Kamada Y-mAbs Therapeutics Amarin Tvardi Therapeutics Aura Biosciences Bright Minds Biosciences Replimune Group DiaMedica Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation. Do analysts rate FDMT or ORMP? 4D Molecular Therapeutics presently has a consensus target price of $30.40, indicating a potential upside of 201.29%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55Oramed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk & volatility, FDMT or ORMP? 4D Molecular Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Does the media favor FDMT or ORMP? In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.83 beat 4D Molecular Therapeutics' score of 0.58 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, FDMT or ORMP? Oramed Pharmaceuticals has higher revenue and earnings than 4D Molecular Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K11,780.08-$160.87M-$3.53-2.86Oramed Pharmaceuticals$2M46.54-$19.06M-$0.35-6.49 Is FDMT or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. Oramed Pharmaceuticals' return on equity of -19.37% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-594,375.81% -40.15% -36.43% Oramed Pharmaceuticals N/A -19.37%-18.28% Do institutionals and insiders have more ownership in FDMT or ORMP? 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Summary4D Molecular Therapeutics and Oramed Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.08M$10.61B$6.13B$10.46BDividend YieldN/A1.91%5.73%4.78%P/E Ratio-6.4920.0185.1527.20Price / Sales46.5426.48573.26177.33Price / CashN/A25.0737.3961.86Price / Book0.633.4212.396.65Net Income-$19.06M$208.83M$3.32B$276.79M7 Day Performance-4.22%-2.34%-0.24%-1.51%1 Month Performance-0.87%1.21%9.56%5.45%1 Year Performance-6.58%-7.89%71.66%36.24% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals0.5559 of 5 stars$2.27flatN/A-3.4%$93.08M$2M-6.4910FDMT4D Molecular Therapeutics3.012 of 5 stars$8.40-1.8%$30.40+261.9%+12.0%$399.31M$40K-2.38120Gap UpENGNenGene3.3498 of 5 stars$7.60-1.9%$19.50+156.6%+4.8%$396.74MN/A-4.0031Analyst ForecastGap DownKMDAKamada4.4778 of 5 stars$6.70-1.8%$13.00+94.0%+25.2%$392.18M$160.95M19.71360Positive NewsYMABY-mAbs Therapeutics1.1445 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150AMRNAmarin0.6236 of 5 stars$19.33+2.6%$12.00-37.9%+73.5%$389.66M$228.61M-5.27360News CoverageHigh Trading VolumeTVRDTvardi Therapeutics2.5344 of 5 stars$40.18-0.1%$64.25+59.9%N/A$377.25M$7.14M0.0080Trending NewsAnalyst DowngradeAnalyst RevisionAURAAura Biosciences1.8119 of 5 stars$5.92-2.1%$22.00+271.6%-35.6%$375.83MN/A-3.0250DRUGBright Minds Biosciences2.9442 of 5 stars$51.50-3.3%$81.00+57.3%+76.8%$375.16MN/A-55.38N/ANews CoveragePositive NewsAnalyst UpgradeREPLReplimune Group4.3555 of 5 stars$4.68-1.1%$6.50+38.9%-55.0%$369.21MN/A-1.44210Positive NewsAnalyst ForecastDMACDiaMedica Therapeutics1.683 of 5 stars$6.93-2.0%$12.33+78.0%+58.4%$365.44MN/A-10.0420 Related Companies and Tools Related Companies 4D Molecular Therapeutics Competitors enGene Competitors Kamada Competitors Y-mAbs Therapeutics Competitors Amarin Competitors Tvardi Therapeutics Competitors Aura Biosciences Competitors Bright Minds Biosciences Competitors Replimune Group Competitors DiaMedica Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
